New Combo Therapy Shows Promising Activity Against AML in Lab Studies

New Combo Therapy Shows Promising Activity Against AML in Lab Studies

285260

New Combo Therapy Shows Promising Activity Against AML in Lab Studies

Combining two potential cancer therapies with distinct modes of action and limited clinical benefits on their own resulted in powerful anti-cancer activity in both cellular and mouse models of acute myeloid leukemia (AML), a study shows. Notably, these benefits were found to be associated with the stabilization of p53 — a tumor suppressor protein — by one therapy, and the blocking of BRD4, a previously unsuspected repressor of p53 target genes, by the other. Together the…

You must be logged in to read/download the full post.